Phase Space Research

BILL Holdings

BILL · Investment summary · as of 12 August 2026

Priced close to what the business has demonstrated

Portfolio decision
No position
Price · 12 August 2026
$48.70
12-month target
$58.10 +19%
Expected return
+19.3%
Next decision point
to August 2026Thesis resolution horizon

Business type: Inflection · scaling but economically observable

The business does not meet the quality standard for its economic type.

Investment view

At $48.70, BILL requires a 7% five-year revenue growth rate to justify its enterprise value — less than the business already delivers, at 12%.

The conditions that would settle the disagreement are dated to August 2026.

The value rests on an exit multiple of 15.9x, a terminal operating margin of 12% and a 8.0% cost of capital. Move any one of them materially and the conclusion moves with it, which is why the required-versus-demonstrated test above carries more weight here than the point value.

Underwriting bridge

QuestionEvidence-based conclusion
What drives the business?Not determined — the operating driver is not stated in one place
What do we forecast?Revenue growth of 12% demonstrated; a terminal operating margin of 12%; an exit multiple of 15.9x.
What does Street forecast?Not determined — no consensus estimates are joined to this record
Where do we differ?On revenue growth, the difference between what the price requires and what the business has demonstrated is +5.4 percentage points.
What is it worth?Twelve-month target $58.10, +19% from the struck price. Scenario-weighted expected return net of costs +19.3%.
Why now?The first dated test of the thesis falls on 19 August 2026.

What must go right

  1. By 19 August 2026FY2027 core revenue growth guided at or above 12%Where it stands: core (subscription + transaction) revenue growth, FY2027 guidance
  2. By each quarterly releaseThe condition does not occur: Take rate declines in two consecutive quartersWhere it stands: transaction fees / TPV
  3. By FY2026 10-K, expected late Aug 2026FY2026 net dollar-based retention at or above 92%Where it stands: NDR, annual disclosure

Catalysts and falsifiers

Date or windowEventThesis confirmed ifThesis weakened or refuted if
19 August 2026Next scheduled resultsRevenue and margin in line with, or above, the house pathA miss that moves the full-year path below the guided floor
19 August 2026Core (subscription + transaction) revenue growth, FY2027 guidanceFY2027 core revenue growth guided at or above 12%FY2027 core revenue growth guided below 12%
each quarterly releaseTransaction fees / TPVNeither leg of the condition opposite is met at this dateTake rate declines in two consecutive quarters
FY2026 10-K, expected late Aug 2026NDR, annual disclosureFY2026 net dollar-based retention at or above 92%FY2026 net dollar-based retention below 92%

Risk and sell discipline

Impairment case

Not determined — no permanent-loss case with a named cause is on file; a bear valuation is not an impairment case

Estimated probability 10%, against the 24% level at which the position would be resized. It sits within that level.

Fundamental invalidation

Falsifiable and fundamental — not one of them is a price condition.

Price-based risk trigger

A daily close below $42.67 triggers an immediate review of the thesis and pauses additional buying. It is not an automatic sell unless a separate fundamental invalidation condition has been breached.

Upside sell discipline

On approach to the $58.10 target the case is reviewed rather than added to; a target reached is a reason to re-examine the position, not to hold it by default. The position is trimmed once forward expected return falls below 0% net of costs, because the capital has a better use elsewhere in the book.

Investment criteria

CriteriaStatusInvestment meaning
QualityNot metIs the business worth owning under its declared economic type?
ValuationMetIs the operating path required by today's price achievable?
LiquidityMetCan the intended position be built and exited in the right vehicle?
DownsideNot determinedWhat is the realistic permanent-loss case? Not established on the evidence on file.
MomentumNot determinedDoes price action support or complicate entry timing? Not established on the evidence on file.
CatalystMetIs there a dated event that resolves the disagreement?
ConsensusNot determinedIs the house-versus-Street disagreement identified and quantified? Not established on the evidence on file.

Quality, valuation and liquidity can prevent a position on their own. The remaining four inform timing, sizing and monitoring, and never reject an investment by themselves.

Bottom line

The strongest case for mispricing is that the business already delivers +5.4 percentage points more growth than the price requires. The most important unresolved uncertainty is whether the operating record is long enough to constrain the terminal value at all. The next evidence that should change the portfolio decision is the test dated 19 August 2026, or a daily close below $42.67, which forces an immediate review.